Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

661 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.
Machiels JP, Licitra LF, Haddad RI, Tahara M, Cohen EE. Machiels JP, et al. Among authors: tahara m. BMC Cancer. 2014 Jun 28;14:473. doi: 10.1186/1471-2407-14-473. BMC Cancer. 2014. PMID: 24973959 Free PMC article. Clinical Trial.
A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy.
Kato K, Tahara M, Hironaka S, Muro K, Takiuchi H, Hamamoto Y, Imamoto H, Amano N, Seriu T. Kato K, et al. Among authors: tahara m. Cancer Chemother Pharmacol. 2011 Jun;67(6):1265-72. doi: 10.1007/s00280-010-1422-x. Epub 2010 Aug 12. Cancer Chemother Pharmacol. 2011. PMID: 20703479 Clinical Trial.
Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer.
Tahara M, Minami H, Hasegawa Y, Tomita K, Watanabe A, Nibu K, Fujii M, Onozawa Y, Kurono Y, Sagae D, Seriu T, Tsukuda M. Tahara M, et al. Cancer Chemother Pharmacol. 2011 Sep;68(3):769-76. doi: 10.1007/s00280-010-1550-3. Epub 2010 Dec 24. Cancer Chemother Pharmacol. 2011. PMID: 21181475 Clinical Trial.
Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial.
Yoshino T, Hasegawa Y, Takahashi S, Monden N, Homma A, Okami K, Onozawa Y, Fujii M, Taguchi T, de Blas B, Beier F, Tahara M. Yoshino T, et al. Among authors: tahara m. Jpn J Clin Oncol. 2013 May;43(5):524-31. doi: 10.1093/jjco/hyt034. Epub 2013 Mar 10. Jpn J Clin Oncol. 2013. PMID: 23479384 Free PMC article. Clinical Trial.
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S, Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA; SPECTRUM investigators. Vermorken JB, et al. Among authors: tahara m. Lancet Oncol. 2013 Jul;14(8):697-710. doi: 10.1016/S1470-2045(13)70181-5. Epub 2013 Jun 6. Lancet Oncol. 2013. PMID: 23746666 Free article. Clinical Trial.
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ; DECISION investigators. Brose MS, et al. Lancet. 2014 Jul 26;384(9940):319-28. doi: 10.1016/S0140-6736(14)60421-9. Epub 2014 Apr 24. Lancet. 2014. PMID: 24768112 Free PMC article. Clinical Trial.
661 results